MedTrace Logo

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

NCT02958865 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 319

Last updated 2022-07-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.

Conditions

Interventions

DRUG

PF-06651600 or Placebo

Delivered orally for 8 weeks.

DRUG

PF-06700841 or Placebo

Delivered orally for 8 weeks.

DRUG

PF-06700841

Delivered orally for 24 weeks.

DRUG

PF-06651600

Delivered orally for 24 weeks.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-03
Primary Completion
2021-05-10
Completion
2021-05-10
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Bulgaria
  • Czechia
  • Denmark
  • Georgia
  • Germany
  • Hungary
  • Israel
  • Italy
  • Poland
  • Romania
  • Russia
  • Serbia
  • Slovakia
  • South Korea
  • Spain
  • Turkey (Türkiye)
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02958865 on ClinicalTrials.gov